Another PRMT5 inhibitor of MRTX1719 exhibits synthetic lethality in preclinical models and activity in phase I trial for patients with MTAP-null cancer (31), The efficacy remains to be investigated in late-stage trials. Here, PRMT5 is linked to cancer.